

REMARKS/ARGUMENTS

By this Amendment, claim 1 is amended. Claims 1-21 are pending.

Citations to the Specification are directed to U.S. Patent Application Publication No. 2008/0242858. Support for the amendments to the claims can be found throughout the Specification as filed, and specifically: support for the amendment to claim 1 can be found in ¶[0047].

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

WITHDRAWN REJECTIONS

Applicant gratefully acknowledges the withdrawal of the rejection of claim 3, 18, and 20.

EX PARTE QUAYLE

The Application stands in condition for allowance except for the objection to claim 21. The Examiner sets forth that the claim as written does not limit claim 1, as claim 1 does not provide for cefixime trihydrate. The Examiner sets forth that Applicant is required to cancel claim 21, rewrite claim 21 in independent form, or amend claim 1 to read "... preparing cefixime or cefixime trihydrate....".

By this Amendment, claim 1 is amended to recite that the process is for the process of preparing cefixime or cefixime trihydrate. Reconsideration and withdrawal of the objection is respectfully traversed.

*

*

*

Application No. 10/598,877
Amendment Dated 12/17/2009
Reply to Office Action of 12/16/2009


For at least the reasons set forth above, it is respectfully submitted that the above-identified application is in condition for allowance. Favorable reconsideration and prompt allowance of the claims are respectfully requested.

Should the Examiner believe that anything further is desirable in order to place the application in even better condition for allowance, the Examiner is invited to contact Applicants' undersigned attorney at the telephone number listed below.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOV, LTD.

December 17, 2009

By 
Joseph F. Murphy
Registration No. 58,313
Customer No. 03000
(215) 567-2010
Attorneys for Applicants

Please charge or credit our
Account No. 03-0075 as necessary
to effect entry and/or ensure
consideration of this submission.